Human E3 ubiquitin-protein ligase MYLIP(MYLIP) ELISA kit

Code CSB-EL015319HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name myosin regulatory light chain interacting protein
Alternative Names BM-023 ELISA Kit; BZF1 ELISA Kit; E3 ubiquitin protein ligase MYLIP ELISA Kit; E3 ubiquitin-protein ligase MYLIP ELISA Kit; Idol ELISA Kit; Inducible degrader of the LDL-receptor ELISA Kit; Lipoprotein receptor ELISA Kit; MIR ELISA Kit; MYLIP ELISA Kit; MYLIP_HUMAN ELISA Kit; Myosin regulatory light chain interacting protein ELISA Kit; PP5242 ELISA Kit
Abbreviation MYLIP
Uniprot No. Q8WY64
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 15.6 pg/mL-1000 pg/mL
Sensitivity 3.9 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Signal Transduction
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human MYLIP in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 105    
Range % 100-110    
1:2 Average % 96    
Range % 92-99    
1:4 Average % 89    
Range % 84-94    
1:8 Average % 93    
Range % 90-96    
Recovery
The recovery of human MYLIP spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 101 99-103    
EDTA plasma (n=4) 90 85-95    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
pg/ml OD1 OD2 Average Corrected    
1000 2.778 2.864 2.821 2.689    
500 2.270 2.305 2.288 2.156    
250 1.520 1.532 1.526 1.394    
125 0.919 0.956 0.938 0.806    
62.5 0.554 0.524 0.539 0.407    
31.2 0.408 0.398 0.403 0.271    
15.6 0.263 0.258 0.261 0.129    
0 0.129 0.134 0.132      
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.
Gene References into Functions
  1. the effects caused by human inducible degrader of the low-density lipoprotein expression are LDLR- dependent given the unchanged plasma lipids in LAhB mice lacking low-density lipoprotein receptor PMID: 26786161
  2. The long noncoding RNA RP1-13D10.2 may contribute to LDL cholesterol levels in response to statins. PMID: 27071970
  3. Specifically, loss of IDOL increases LDLR distribution in the hepatic cell, and subsequently reduces serum LDL-C levels in dyslipidemic patients PMID: 26601593
  4. Data suggest inducible expression of IDOL is subject to robust, rapid regulation by process that is sensitive to deubiquitinase inhibition in human/mouse cell lines and primary human cells; transcriptional induction of IDOL leads to degradation of LDLR. PMID: 26719329
  5. Identify USP2 as a novel regulator of lipoprotein clearance owing to its ability to control ubiquitylation-dependent degradation of the LDLR by IDOL. PMID: 26666640
  6. The study identified MARCH6 as a negative regulator of SREBP2-mediated transcription and described an unexpected E3 circuit functionally linking MARCH6 and IDOL to limit uptake of low-density lipoprotein via the LDLR pathway. PMID: 26527619
  7. IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. PMID: 25927920
  8. Several lipid-related gene polymorphisms interact with overweight/obesity to modulate blood pressure levels. PMID: 23109900
  9. study indicates that MYLIP p.N342S might be a pharmacogenetic marker for lipid-lowering therapy in patients with FH. PMID: 25171759
  10. Liver-specific expression of dominant-active IDOL is associated with hypercholesterolemia and a marked elevation in atherosclerotic lesions in transgenic mice. PMID: 24935961
  11. Results show that IDOL contributes to variation in circulating levels of LDL-C. PMID: 23324548
  12. IDOL is recruited to plasma membrane by low-density lipoprotein receptor (LDLR), promotes LDLR internalization in the absence of clathrin or caveolae, and facilitates LDLR degradation by shuttling it into the multivesicular body protein-sorting pathway PMID: 23382078
  13. MYLIP rs3757354 SNP is associated with serum TC, HDL-C and ApoAI levels in the Bai Ku Yao and Han populations. But the association is different between the two ethnic groups. PMID: 23107276
  14. No association of the MYLIP rs9370867 genotypes with lipid profile, hemodynamic data, and coronary angiographic data was in a Brazilian population. PMID: 22741812
  15. FGF21 also enhanced expression of Canopy2 (Cnpy2)/MIR-interacting Saposin-like protein (Msap) that is known to interact with Mylip/Idol. PMID: 22378787
  16. expression levels rise with increasing age in hearts of men PMID: 22261164
  17. both the FERM and RING domains are required for promoting lysosomal degradation of the LDLR by IDOL. PMID: 21734303
  18. N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans PMID: 21765216
  19. identify the IDOL-UBE2D complex as an important determinant of LDLR activity, and provide insight into molecular mechanisms underlying the regulation of cholesterol uptake PMID: 21685362
  20. Data report that statins exert opposite effects on PCSK9 and Idol gene expression in human hepatoma-derived cell lines and primary hepatocytes isolated from hamsters and rats. PMID: 21069265
  21. MSAP interacts with this protein that enhances neurite outgrowth and increases myosin regulatory light chain in fetal and adult brain. PMID: 12826659
  22. c-MIR is the first example of an E3 ubiquitin ligase that is capable of inhibiting major histocompatibility (MHC) class II expression in antigen-presenting cells; c-MIR might potently regulate immune responses in vivo. PMID: 16785530
  23. study shows the LXR-Idol(Mylip)-LDLR axis defines a complementary pathway to sterol response element-binding proteins for sterol regulation of cholesterol uptake PMID: 19520913
  24. Novel insights into the physiology of this receptor come from studies on the ubiquitination and degradation of LDL receptor by the ubiquitin ligase Mylip/Idol that is induced in cells by the nuclear receptor, LXR. PMID: 19688294

Show More

Hide All

Subcellular Location Cytoplasm. Cell membrane; Peripheral membrane protein.
Tissue Specificity Ubiquitously expressed.
Database Links

HGNC: 21155

OMIM: 610082

KEGG: hsa:29116

STRING: 9606.ENSP00000349298

UniGene: Hs.484738

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1